Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shannon R Morris

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Advances in Therapy|October 30, 2020
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II StudyLowell L Hart, Renata Ferrarotto, Zoran G Andric, et al.
Pediatric Blood & Cancer|November 3, 2016
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosisRobert J Arceci, Carl E Allen, Ira J Dunkel, et al.
Investigational New Drugs|April 4, 2018
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumorsCarol Aghajanian, Katherine M Bell-McGuinn, Howard A Burris, et al.
The Lancet. Oncology|October 3, 2019
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trialAntoinette R Tan, Gail S Wright, Anu R Thummala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor MalignanciesPamela Munster, Rahul Aggarwal, David Hong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2015
Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic MalignanciesHatice Gungor, Azeem Saleem, Syed Babar, et al.
The Lancet. Oncology|July 19, 2012
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialJeffrey R Infante, Leslie A Fecher, Gerald S Falchook, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Advances in Therapy|October 30, 2020
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II StudyLowell L Hart, Renata Ferrarotto, Zoran G Andric, et al.
Pediatric Blood & Cancer|November 3, 2016
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosisRobert J Arceci, Carl E Allen, Ira J Dunkel, et al.
Investigational New Drugs|April 4, 2018
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumorsCarol Aghajanian, Katherine M Bell-McGuinn, Howard A Burris, et al.
The Lancet. Oncology|October 3, 2019
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trialAntoinette R Tan, Gail S Wright, Anu R Thummala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor MalignanciesPamela Munster, Rahul Aggarwal, David Hong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2015
Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic MalignanciesHatice Gungor, Azeem Saleem, Syed Babar, et al.
The Lancet. Oncology|July 19, 2012
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialJeffrey R Infante, Leslie A Fecher, Gerald S Falchook, et al.
Pageof 2